Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2011, Article ID 348297, 11 pages
http://dx.doi.org/10.4061/2011/348297
Review Article

Targeted Therapy in Hepatocellular Carcinoma

Department of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610

Received 18 January 2011; Accepted 1 March 2011

Academic Editor: Thomas Leung

Copyright © 2011 Clarinda W. L. Chua and Su Pin Choo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Google Scholar · View at Scopus
  2. F. Pons-Renedo and J. M. Llovet, “Hepatocellular carcinoma: a clinical update,” MedGenMed Medscape General Medicine, vol. 5, no. 3, 2003. View at Google Scholar · View at Scopus
  3. J. M. Llovet, A. Burroughs, and J. Bruix, “Hepatocellular carcinoma,” Lancet, vol. 362, no. 9399, pp. 1907–1917, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Tsukuma, T. Hiyama, S. Tanaka et al., “Risk factors for hepatocellular carcinoma among patients with chronic liver disease,” New England Journal of Medicine, vol. 328, no. 25, pp. 1797–1801, 1993. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Huang and G. Liu, “The study of innate drug resistance of human hepatocellular carcinoma Bel cell line,” Cancer Letters, vol. 135, no. 1, pp. 97–105, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Okada, N. Okazaki, H. Nose, Y. Shimada, M. Yoshimori, and K. Aoki, “A phase 2 study of cisplatin in patients with hepatocellular carcinoma,” Oncology, vol. 50, no. 1, pp. 22–26, 1993. View at Google Scholar · View at Scopus
  7. T. S. Yang, Y. C. Lin, J. S. Chen, H. M. Wang, and C. H. Wang, “Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma,” Cancer, vol. 89, no. 4, pp. 750–756, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Z. Patt, M. M. Hassan, A. Aguayo et al., “Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma,” Cancer, vol. 101, no. 3, pp. 578–586, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Okada, “Chemotherapy for hepatocellular carcinoma,” in Liver Cancer, K. Okuda and E. Tabor, Eds., pp. 441–448, Churchill Livingstone, New York, NY, USA, 1997. View at Google Scholar
  10. G. Falkson, L. M. Ryan, L. A. Johnson et al., “A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study,” Cancer, vol. 60, no. 9, pp. 2141–2145, 1987. View at Google Scholar · View at Scopus
  11. S. R. Nerenstone, D. C. Ihde, and M. A. Friedman, “Clinical trials in primary hepatocellular carcinoma: current status and future directions,” Cancer Treatment Reviews, vol. 15, no. 1, pp. 1–31, 1988. View at Google Scholar · View at Scopus
  12. H. S. Hochster, M. D. Green, and J. Speyer, “4'Epioxorubicin (Epirubicin): activity in hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 3, no. 11, pp. 1535–1540, 1985. View at Google Scholar
  13. W. Yeo, T. S. Mok, B. Zee et al., “A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma,” Journal of the National Cancer Institute, vol. 97, no. 20, pp. 1532–1538, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Lombardi, F. Zustovich, F. Farinati et al., “Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study,” Cancer, vol. 117, no. 1, pp. 125–133, 2011. View at Publisher · View at Google Scholar
  15. G. K. Abou-Alfa, “Current and novel therapeutics for hepatocellular carcinoma,” in American Society of Clinical Oncology Educational Handbook, pp. 192–197, American Society of Clinical Oncology, Alexandria, Va, USA, 2004. View at Google Scholar
  16. E. Bugianesi, “Review article: steatosis, the metabolic syndrome and cancer,” Alimentary Pharmacology and Therapeutics, vol. 22, no. 2, supplement, pp. 40–43, 2005. View at Google Scholar · View at Scopus
  17. S. Whittaker, R. Marais, and A. X. Zhu, “The role of signaling pathways in the development and treatment of hepatocellular carcinoma,” Oncogene, vol. 29, no. 36, pp. 4989–5005, 2010. View at Publisher · View at Google Scholar
  18. S. S. Thorgeirsson and J. W. Grisham, “Molecular pathogenesis of human hepatocellular carcinoma,” Nature Genetics, vol. 31, no. 4, pp. 339–346, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. X. W. Wang, S. P. Hussain, T. I. Huo et al., “Molecular pathogenesis of human hepatocellular carcinoma,” Toxicology, vol. 181-182, pp. 43–47, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. M. A. Feitelson, J. Pan, and Z. Lian, “Early molecular and genetic determinants of primary liver malignancy,” Surgical Clinics of North America, vol. 84, no. 2, pp. 339–354, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Marotta, B. Vangieri, A. Cecere, and A. Gattoni, “The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect,” Clinica Terapeutica, vol. 155, no. 5, pp. 187–199, 2004. View at Google Scholar · View at Scopus
  22. A. Villanueva, D. Y. Chiang, P. Newell et al., “Pivotal role of mTOR signaling in hepatocellular carcinoma,” Gastroenterology, vol. 135, no. 6, pp. 1972–1983, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Villanueva, P. Newell, D. Y. Chiang, S. L. Friedman, and J. M. Llovet, “Genomics and signaling pathways in hepatocellular carcinoma,” Seminars in Liver Disease, vol. 27, no. 1, pp. 55–76, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. A. B. Siegel, S. K. Olsen, A. Magun, and R. S. Brown Jr., “Sorafenib: where do we go from here?” Hepatology, vol. 52, no. 1, pp. 360–369, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Höpfner, D. Schuppan, and H. Scherübl, “Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer,” World Journal of Gastroenterology, vol. 14, no. 1, pp. 1–14, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Yoshiji, S. Kuriyama, J. Yoshii et al., “Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells,” Hepatology, vol. 28, no. 6, pp. 1489–1496, 1998. View at Google Scholar · View at Scopus
  27. W. S. Moon, K. H. Rhyu, M. J. Kang et al., “Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?” Modern Pathology, vol. 16, no. 6, pp. 552–557, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Shimamura, S. Saito, K. Morita et al., “Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens,” Journal of Gastroenterology and Hepatology, vol. 15, no. 6, pp. 640–646, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. I. O. L. Ng, R. T. P. Poon, J. M. F. Lee, S. T. Fan, M. Ng, and W. K. Tso, “Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma,” American Journal of Clinical Pathology, vol. 116, no. 6, pp. 838–845, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. D. K. Dhar, H. Naora, A. Yamanoi et al., “Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway,” Anticancer Research, vol. 22, no. 1 A, pp. 379–386, 2002. View at Google Scholar · View at Scopus
  31. R. T. P. Poon, J. W. Y. Ho, C. S. W. Tong, C. Lau, I. O. L. Ng, and S. T. Fan, “Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma,” British Journal of Surgery, vol. 91, no. 10, pp. 1354–1360, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. Z. Lian, J. Liu, M. Wu et al., “Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis,” Hepatology, vol. 45, no. 6, pp. 1390–1399, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Wilhelm and D. S. Chien, “BAY 43-9006: preclinical data,” Current Pharmaceutical Design, vol. 8, no. 25, pp. 2255–2257, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Liu, Y. Cao, C. Chen et al., “Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5,” Cancer Research, vol. 66, no. 24, pp. 11851–11858, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. G. K. Abou-Alfa, L. Schwartz, S. Ricci et al., “Phase II study of sorafenib in patients with advanced hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4293–4300, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. T. W. T. Leung, Y. Z. Patt, W. Y. Lau et al., “Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma,” Clinical Cancer Research, vol. 5, no. 7, pp. 1676–1681, 1999. View at Google Scholar · View at Scopus
  37. J. Lee, J. O. Park, W. S. Kim et al., “Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma,” Cancer Chemotherapy and Pharmacology, vol. 54, no. 5, pp. 385–390, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. A. L. Cheng, Y. K. Kang, Z. Chen et al., “Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial,” The Lancet Oncology, vol. 10, no. 1, pp. 25–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Google Scholar · View at Scopus
  41. Y. Chung, B. Kim, C. Chen et al., “Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): second interim safety and efficacy analysis,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, ASCO abstract 4026. View at Google Scholar
  42. G. K. Abou-Alfa, P. Johnson, J. J. Knox et al., “Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial,” Journal of the American Medical Association, vol. 304, no. 19, pp. 2154–2160, 2010. View at Publisher · View at Google Scholar
  43. A. B. Siegel, E. I. Cohen, A. Ocean et al., “Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 26, no. 18, pp. 2992–2998, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. A. X. Zhu, L. S. Blaszkowsky, D. P. Ryan et al., “Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 24, no. 12, pp. 1898–1903, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. W. Sun, D. G. Haller, K. Mykulowycz, M. Rosen, M. Soulen, and M. Capparo, “Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study,” Journal of Clinical Oncology, vol. 25, no. 18, supplement, 2007. View at Google Scholar
  46. C. H. Hsu, T. S. Yang, C. Hsu et al., “Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma,” British Journal of Cancer, vol. 102, no. 6, pp. 981–986, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. M. B. Thomas, J. S. Morris, R. Chadha et al., “Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 27, no. 6, pp. 843–850, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. A. X. Zhu, D. V. Sahani, D. G. Duda et al., “Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study,” Journal of Clinical Oncology, vol. 27, no. 18, pp. 3027–3035, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Faivre, E. Raymond, E. Boucher et al., “Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study,” The Lancet Oncology, vol. 10, no. 8, pp. 794–800, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Toh, P. Chen, B. I. Carr et al., “A phase II study of ABT-869 in hepatocellular carcinoma (HCC): interim analysis,” Journal of Clinical Oncology, vol. 27, no. 15, supplement, 2009. View at Google Scholar
  51. P. A. Philip, M. R. Mahoney, C. Allmer et al., “Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer,” Journal of Clinical Oncology, vol. 23, no. 27, pp. 6657–6663, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. M. B. Thomas, R. Chadha, K. Glover et al., “Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma,” Cancer, vol. 110, no. 5, pp. 1059–1067, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. M. C. Cantarini, F. Trevisani, A. M. Morselli-Labate et al., “Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma,” American Journal of Gastroenterology, vol. 101, no. 1, pp. 91–98, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. F. D. Huitzil-Melendez, L. B. Saltz, J. Song et al., “Retrospective analysis of outcome in hepatocellular carcinoma patients with hepatitis C versus B treated with sorafenib,” in Proceedings of the American Society of Clinical Oncology on Gastrointest Cancer Symposium, 2007, abstract 173.
  55. Z. Guan, Y. Kang, Z. Chen et al., “Sorafenib is effective in hepatitis B-positive patients with hepatocellular carcinoma: subgroup analysis of a randomized, double-blind, phase III trial performed in the Asia-Pacifi c region,” Annals of Oncology, vol. 19, supplement 8, pp. 166–186, 2008. View at Google Scholar
  56. L. Bolondi, W. Caspary et al., “Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial,” in Proceedings of the ASCO Gastrointestinal Cancers Symposium, 2008, abstract 129.
  57. G. K. Abou-Alfa, D. Amadori et al., “Is sorafenib safe and effective in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis?” Journal of Clinical Oncology, vol. 26, supplement, 2008, ASCO Annual Meeting. Abstract 4518. View at Google Scholar
  58. M. Pinter, W. Sieghart, I. Graziadei et al., “Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis,” Oncologist, vol. 14, no. 1, pp. 70–76, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. A. A. Miller, D. J. Murry, K. Owzar et al., “Phase i and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301,” Journal of Clinical Oncology, vol. 27, no. 11, pp. 1800–1805, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. National Cancer Institute clinical trials Web page. Phase III randomized study of sorafenib tosylate with versus without doxorubicin hydrochloride in patients with locally advanced or metastatic hepatocellular carcinoma. 2010, http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=659348&version=HealthProfessional &protocolsearchid=7262229.
  61. T. Yau and P. Chan, “Phase II trial of sorafenib with capecitabine and oxaliplatin (SECOX) in patients with locally advanced or metastatic hepatocellular carcinoma,” in Proceedings of the 34th ESMO Multidisciplinary Congress Abstract, vol. 7, no. 3, pp. 20–21, 2009, EJC Supplements.
  62. L. G. Presta, H. Chen, S. J. O'Connor et al., “Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders,” Cancer Research, vol. 57, no. 20, pp. 4593–4599, 1997. View at Google Scholar · View at Scopus
  63. L. J. Murray, T. J. Abrams, K. R. Long et al., “SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model,” Clinical and Experimental Metastasis, vol. 20, no. 8, pp. 757–766, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. T. J. Abrams, L. B. Lee, L. J. Murray, N. K. Pryer, and J. M. Cherrington, “SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer,” Molecular Cancer Therapeutics, vol. 2, pp. 471–478, 2003. View at Google Scholar
  65. T. J. Abrams, L. J. Murray, E. Pesenti et al., “Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer,” Molecular Cancer Therapeutics, vol. 2, no. 10, pp. 1011–1021, 2003. View at Google Scholar · View at Scopus
  66. D. H. Albert, P. Tapang, T. J. Magoc et al., “Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor,” Molecular Cancer Therapeutics, vol. 5, no. 4, pp. 995–1006, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC). US National Institutes of Health, http://clinicaltrials.gov/ct2/show/NCT01009593.
  68. J. L. Raoul, R. S. Finn, Y. K. Kang, J. W. Park, R. Harris, and V. Coric, “An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma(HCC),” Journal of Clinical Oncology, vol. 27, no. 15, supplement, 2009. View at Google Scholar
  69. A. F. Buckley, L. J. Burgart, V. Sahai, and S. Kakar, “Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma,” American Journal of Clinical Pathology, vol. 129, no. 2, pp. 245–251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. E. Schiffer, C. Housset, W. Cacheux et al., “Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis,” Hepatology, vol. 41, no. 2, pp. 307–314, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Altimari, M. Fiorentino, E. Gabusi et al., “Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours,” Digestive and Liver Disease, vol. 35, no. 5, pp. 332–338, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib,” New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. M. J. Moore, D. Goldstein, J. Hamm et al., “Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1960–1966, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Schiffer, C. Housset, W. Cacheux et al., “Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis,” Hepatology, vol. 41, no. 2, pp. 307–314, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. L. Nakopoulou, K. Stefanaki, D. Filaktopoulos, and I. Giannopoulou, “C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study,” Histology and Histopathology, vol. 9, no. 4, pp. 677–682, 1994. View at Google Scholar · View at Scopus
  76. A. Huether, M. Höpfner, A. P. Sutter, D. Schuppan, and H. Scherübl, “Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics,” Journal of Hepatology, vol. 43, no. 4, pp. 661–669, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Matsuo, H. Sakurai, and I. Saiki, “ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model,” Molecular cancer therapeutics, vol. 2, no. 6, pp. 557–561, 2003. View at Google Scholar · View at Scopus
  78. S. I. Ueda, Y. Basaki, M. Yoshie et al., “PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib,” Cancer Research, vol. 66, no. 10, pp. 5346–5353, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. J. I. Okano, K. Matsumoto, T. Nagahara, and Y. Murawaki, “Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells,” Journal of Gastroenterology, vol. 41, no. 2, pp. 166–176, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Whittaker, R. Marais, and A. X. Zhu, “The role of signaling pathways in the development and treatment of hepatocellular carcinoma,” Oncogene, vol. 29, no. 36, pp. 4989–5005, 2010. View at Publisher · View at Google Scholar
  81. P. J. O’Dwyer, B. J. Giantonio, D. E. Levy, J. S. Kauh, D. B. Fitzgerald, and A. B. Benson III, “Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group’s Study E1203,” Journal of Clinical Oncology, vol. 24, no. 213, supplement, 2006. View at Google Scholar
  82. A. X. Zhu, K. Stuart, L. S. Blaszkowsky et al., “Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma,” Cancer, vol. 110, no. 3, pp. 581–589, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. V. Gruenwald, V. Wilkens, M. Gebel, T. F. Greten, S. Kubicka, and A. Ganser, “A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results,” Journal of Clinical Oncology, vol. 25, no. 222, supplement, 2007. View at Google Scholar
  84. F. Ciardiello, T. Troiani, R. Bianco et al., “Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy,” Annals of Oncology, vol. 17, no. 7, pp. vii109–vii114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. G. Tortora, R. Caputo, V. Damiano et al., “Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect,” Clinical Cancer Research, vol. 9, no. 4, pp. 1566–1572, 2003. View at Google Scholar · View at Scopus
  86. M. Ganslmayer, M. Ocker, G. Kraemer et al., “The combination of tamoxifen and 9cis retinoic acid exerts overadditive anti-tumoral efficacy in rat hepatocellular carcinoma,” Journal of Hepatology, vol. 40, no. 6, pp. 952–956, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Ganslmayer, M. Ocker, S. Zopf et al., “A quadruple therapy synergistically blocks proliferation and promotes apoptosis of hepatoma cells,” Oncology reports, vol. 11, no. 5, pp. 943–950, 2004. View at Google Scholar · View at Scopus
  88. C. Herold, M. Ganslmayer, M. Ocker et al., “Overadditive anti-proliferative and pro-apoptotic effects of a combination therapy on colorectal carcinoma cells,” International Journal of Oncology, vol. 23, pp. 751–756, 2003. View at Google Scholar
  89. C. Alexia, G. Fallot, M. Lasfer, G. Schweizer-Groyer, and A. Groyer, “An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis,” Biochemical Pharmacology, vol. 68, no. 6, pp. 1003–1015, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. C. K. Tsang, H. Qi, L. F. Liu, and X. F. S. Zheng, “Targeting mammalian target of rapamycin (mTOR) for health and diseases,” Drug Discovery Today, vol. 12, no. 3-4, pp. 112–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Rizell, M. Andersson, C. Cahlin, L. Hafström, M. Olausson, and P. Lindnér, “Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer,” International Journal of Clinical Oncology, vol. 13, no. 1, pp. 66–70, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. L. Dudkin, M. B. Dilling, P. J. Cheshire et al., “Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition,” Clinical Cancer Research, vol. 7, no. 6, pp. 1758–1764, 2001. View at Google Scholar · View at Scopus
  93. J. B. Easton and P. J. Houghton, “mTOR and cancer therapy,” Oncogene, vol. 25, no. 48, pp. 6436–6446, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Wullschleger, R. Loewith, and M. N. Hall, “TOR signaling in growth and metabolism,” Cell, vol. 124, no. 3, pp. 471–484, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. H. Huynh, K. H. Pierce Chow, K. C. Soo et al., “RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma,” Journal of Cellular and Molecular Medicine, vol. 13, no. 7, pp. 1371–1380, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. H. Huynh, V. C. Ngo, H. N. Koong et al., “Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma,” Journal of Cellular and Molecular Medicine, vol. 13, no. 8, pp. 2673–2683, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. E. R. Camp, J. Summy, T. W. Bauer, W. Liu, G. E. Gallick, and L. M. Ellis, “Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor,” Clinical Cancer Research, vol. 11, no. 1, pp. 397–405, 2005. View at Google Scholar · View at Scopus